About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Neural Circulatory Control and SUDEP Risk. | Clinical Trials | Clareo Health

Back to clinical trial search

Active Not RecruitingNCT02813980

Neural Circulatory Control and SUDEP Risk.

The investigators believe epilepsy alters the way the body controls blood pressure, heart rate and breathing, and these changes increase the risk of sudden unexpected death in patients with epilepsy (...

Lead sponsor: Mayo Clinic•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Mayo Clinic

Collaborators

American Heart Association

The investigators overall goals are to determine whether measures of neural-circulatory control during the interictal waking and sleep states, as well as during the ictal/peri-ictal periods, are associated with SUDEP-7 score risk profiles in refractory epilepsy patients, and to translate these measures into tools for risk-stratification and preventative strategies for SUDEP.

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adults aged 18-90
•Able to consent

Exclusion Criteria

•History of non-epileptic spells/seizures,
•Children/adolescents under age 18 years
•Pregnancy
•Non-compliance with Epilepsy Monitoring Unit safety procedures
•Unable to consent
•History of dysautonomia
•Chronic Obstructive Pulmonary Disease (COPD)
•Asthma (active requiring therapy)
•Pulmonary hypertension
•Known Structural Heart Disease
•Heart failure
•Myocardial infarction
•Stroke
•Seizures due to traumatic injury
•Prior surgery for epilepsy
•Vasculitis
•Raynaud's
•Smoking (current or within the last 6 months)

Related studies

RECRUITINGPhase 3

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904 · Stereotypical Prolonged Seizures

RECRUITINGPhase 1

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

NCT02531880 · Epilepsy

The Clinical Utility of BioEP in Diagnostic Decision Making in Epilepsy

NCT06097195 · Epilepsy

RECRUITINGPhase 3

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

NCT06315322 · Childhood Absence Epilepsy, Juvenile Absence Epilepsy

RECRUITINGPhase 1/2

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

NCT06388707 · Drug Resistant Epilepsy, Epilepsy, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 18, 2025Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

Phase—

Enrollment39

Start dateJun 2016

Last updatedJun 18, 2025

Condition

Epilepsy Seizures

Locations shown

Mayo Clinic

Rochester, Minnesota

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 18, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions